[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Apogee Therapeutics Inc (APGE)

Apogee Therapeutics Inc (APGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Apogee Therapeutics Reports Monday With Clinical Data Still Hanging Over Every Analyst Assumption

Apogee Therapeutics (APGE) reports Q1 2026 earnings before the market opens on Monday, May 11, with analysts expecting the clinical-stage biotech to post a loss of $1.12 per share. The central question: can APGE demonstrate continued progress in its pipeline of differentiated biologics for immunological and inflammatory diseases while managing its cash burn rate? With the stock trading at $83.03 and Wall Street maintaining a strong bullish stance—15 of 19 analysts rate it a Strong Buy—investors will scrutinize clinical trial updates and runway guidance as the company advances its lead programs targeting atopic dermatitis and other IL-13/IL-4 driven conditions.

Fundamentals

See More
  • Market Capitalization, $K 5,135,655
  • Shares Outstanding, K 61,853
  • Annual Sales, $ 0 K
  • Annual Income, $ -255,840 K
  • EBIT $ -286 M
  • EBITDA $ -292 M
  • 60-Month Beta 0.69
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.18

Options Overview Details

View History
  • Implied Volatility 74.01% (+4.12%)
  • Historical Volatility 34.90%
  • IV Percentile 67%
  • IV Rank 13.12%
  • IV High 236.20% on 06/20/25
  • IV Low 49.53% on 12/10/25
  • Expected Move (DTE 5) 6.64 (8.00%)
  • Put/Call Vol Ratio 0.85
  • Today's Volume 120
  • Volume Avg (30-Day) 479
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 5,990
  • Open Int (30-Day) 8,499
  • Expected Range 76.39 to 89.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.12
  • Number of Estimates 4
  • High Estimate $-1.05
  • Low Estimate $-1.22
  • Prior Year $-0.95
  • Growth Rate Est. (year over year) -17.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
80.52 +3.12%
on 05/04/26
95.32 -12.89%
on 04/17/26
-0.09 (-0.11%)
since 04/08/26
3-Month
60.35 +37.58%
on 02/09/26
95.32 -12.89%
on 04/17/26
+20.79 (+33.40%)
since 02/06/26
52-Week
34.34 +141.79%
on 08/08/25
95.32 -12.89%
on 04/17/26
+45.22 (+119.60%)
since 05/08/25

Most Recent Stories

More News
Apogee Therapeutics Reports Monday With Clinical Data Still Hanging Over Every Analyst Assumption

Barchart Research What to Expect from APGE Earnings APGE Generated May 8, 2026 Current Price $83.03 EPS Estimate $$-1.12 Consensus Rating Strong Buy Average Move 4.29% Apogee Therapeutics Reports Monday...

APGE : 83.03 (+1.49%)
Apogee Therapeutics Reports Monday With Clinical Data Still Hanging Over Every Analyst Assumption

Barchart Research What to Expect from APGE Earnings APGE Generated May 8, 2026 Current Price $83.03 EPS Estimate $$-1.12 Consensus Rating Strong Buy Average Move 4.29% Apogee Therapeutics Reports Monday...

APGE : 83.03 (+1.49%)
Apogee Therapeutics Reports Monday With Clinical Data Still Hanging Over Every Analyst Assumption

Barchart Research What to Expect from APGE Earnings APGE Generated May 8, 2026 Current Price $83.03 EPS Estimate $$-1.12 Consensus Rating Strong Buy Average Move 4.29% Apogee Therapeutics Reports Monday...

APGE : 83.03 (+1.49%)
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million

SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for...

APGE : 83.03 (+1.49%)
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for...

APGE : 83.03 (+1.49%)
Stocks Sharply Higher as President Trump Seeks to End Iran War

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +1.15%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +1.38%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.22%. June E-mini S&P...

ALK : 40.84 (+0.62%)
GOOGL : 400.80 (+0.71%)
AAPL : 293.32 (+2.05%)
TRI : 92.94 (-0.46%)
TSLA : 428.35 (+4.02%)
VVV : 35.62 (-0.70%)
SPY : 737.62 (+0.83%)
INSM : 101.35 (-3.48%)
DKNG : 25.52 (+1.19%)
META : 609.63 (-1.16%)
EL : 86.20 (+1.07%)
AAL : 13.35 (+1.29%)
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

SAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for...

APGE : 83.03 (+1.49%)
Stocks Rally as President Trump Eases Iran Threats

The S&P 500 Index ($SPX ) (SPY ) today is up +2.10%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +2.30%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.19%. June E-mini S&P futures (ESM26...

ALK : 40.84 (+0.62%)
GOOGL : 400.80 (+0.71%)
AAPL : 293.32 (+2.05%)
ADI : 416.52 (+1.96%)
TRI : 92.94 (-0.46%)
TSLA : 428.35 (+4.02%)
WDC : 480.00 (+3.47%)
VVV : 35.62 (-0.70%)
AMD : 455.19 (+11.44%)
SPY : 737.62 (+0.83%)
INSM : 101.35 (-3.48%)
DKNG : 25.52 (+1.19%)
Stocks Rebound as Crude Oil Sinks After President Trump Eases Iran Threats

The S&P 500 Index ($SPX ) (SPY ) today is up +1.73%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.97%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.79%. June E-mini S&P futures (ESM26...

ALK : 40.84 (+0.62%)
GOOGL : 400.80 (+0.71%)
UAL : 99.58 (-0.12%)
AAPL : 293.32 (+2.05%)
DHI : 147.63 (+1.14%)
BLDR : 77.40 (-2.53%)
$IUXX : 29,234.99 (+2.35%)
ZNM26 : 110-175 (-0.18%)
MSFT : 415.12 (-1.34%)
KBH : 49.52 (+0.69%)
TSLA : 428.35 (+4.02%)
APGE : 83.03 (+1.49%)
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis

APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including: - 75% and 85% patients maintained EASI-75 - 86% and 78% patients...

APGE : 83.03 (+1.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Apogee Therapeutics LLC is a biotechnology company advancing novel, potentially therapies to address the needs of the millions of people living with immunological and inflammatory disorders. Apogee Therapeutics LLC is based in SAN FRANCISCO.

See More

Key Turning Points

3rd Resistance Point 86.19
2nd Resistance Point 85.17
1st Resistance Point 84.10
Last Price 83.03
1st Support Level 82.01
2nd Support Level 80.99
3rd Support Level 79.92

See More

52-Week High 95.32
Last Price 83.03
Fibonacci 61.8% 72.02
Fibonacci 50% 64.83
Fibonacci 38.2% 57.63
52-Week Low 34.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.